Company Profile (AI Text)
Name: Myosana Therapeutics
Canonical URL: https://wefunder.com/myosana.therapeutics
Updated at: 2026-06-02T23:55:22Z

Tagline: Get a Piece of Myosana Therapeutics  

Key claims:
- Total raised on Wefunder: 288246 | citation: https://wefunder.com/myosana.therapeutics#claim-total-raised
- Total investors: 24 | citation: https://wefunder.com/myosana.therapeutics#claim-total-investors

Verified facts:
- Total raised on Wefunder: 288246 | observed_at: 2026-06-02T23:55:22Z | expires_at: 2026-06-03T23:55:22Z
- Total investors: 24 | observed_at: 2026-06-02T23:55:22Z | expires_at: 2026-06-03T23:55:22Z

Computed metrics:
- total_amount_raised: 288246
- total_investors: 24
- team_size: 3
- featured_investor_count: 4
- faq_count: 0
- recent_post_count: 0

Quick facts:
- Developing a gene therapy treatment for Duchenne muscular dystrophy (DMD). | citation: https://wefunder.com/myosana.therapeutics#claim-fact-1
- Designed to deliver full-length dystrophin to skeletal and cardiac muscle. | citation: https://wefunder.com/myosana.therapeutics#claim-fact-2
- Uses proprietary GLUT4-targeting antibodies to deliver DNA to muscle cells efficiently. | citation: https://wefunder.com/myosana.therapeutics#claim-fact-3
- Non-viral design allows repeat dosing, unlike most viral gene therapies. | citation: https://wefunder.com/myosana.therapeutics#claim-fact-4
- Investment from Parent Project Muscular Dystrophy, CureDuchenne Ventures, angel investor. | citation: https://wefunder.com/myosana.therapeutics#claim-fact-5
- Preclinical studies show significant dystrophin expression in DMD animal models. | citation: https://wefunder.com/myosana.therapeutics#claim-fact-6
- DMD treatment market projected to reach about $10B by 2030. | citation: https://wefunder.com/myosana.therapeutics#claim-fact-7
- A founding team with extensive experience in neuromuscular disease research and drug development. | citation: https://wefunder.com/myosana.therapeutics#claim-fact-8